CCCC News and Press, C4 Therapeutics Inc.

WATERTOWN, Mass., July 16, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that preliminary data from the monotherapy dose escalation portion of the ongoing...

WATERTOWN, Mass., July 08, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that C4T management will participate in a fireside chat at the UBS Targeted Prote...

2024-06-13 11:33:07 ET Summary C4 Therapeutics focused on protein degraders, with recent financial updates and guidance for 2024 catalysts. The pipeline includes Cemsidomide for multiple myeloma and CFT1946 for melanoma, with ongoing dose escalation trials. Financially, CCCC r...

Cooper Brings Decades of Global Pharmaceutical and Biotechnology Leadership Experience Bruce Downey Remains a Member of the Board of Directors and Chair of the Organization, Leadership and Compensation Committee Transition Further Highlights Commitment to Strategically Transform t...

2024-05-08 13:54:22 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips C4 Therapeutics (NASDAQ: CCCC ) just reported results for the first quarter of 2024. C4 Therapeutics reported earnings per share of -41 cents. This was below the analyst e...

2024-05-08 11:26:56 ET C4 Therapeutics press release ( NASDAQ: CCCC ): Q1 GAAP EPS of -$0.41 in-line. Revenue of $3.04M (-19.1% Y/Y) misses by $6.24M . Cash, cash equivalents and marketable securities as of March 31, 2024 were $299.2 million, compared to $281.7 mil...

Successfully Delivered First Development Candidate to Biogen; $8 Million Payment Earned Established a Strategic Discovery Research Collaboration with Merck KGaA, Darmstadt, Germany, Focused on Two Critical Oncogenic Proteins Progressed Phase 1 Dose Escalation Trials for Cemsidom...

2024-05-06 09:34:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

Resideo Technologies Inc. (REZI) is expected to report $0.33 for Q1 2024 Schneider National Inc. (SNDR) is expected to report $0.13 for Q1 2024 Murphy Oil Corporation (MUR) is expected to report $0.82 for Q1 2024 Astronics Corp. - Class B (ATROB) is expected to report for Q1 2024 ...

WATERTOWN, Mass., April 29, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that the independent directors serving on the Organization, Leadership and Compe...